Published in Drug Week, April 29th, 2005
This is the first-ever approval of Impavido for this form of leishmaniasis. The approval also applies for the visceral form (black fever) of leishmaniasis for which Impavido had already received approval by the Indian and German Regulatory Authorities. Impavido thus becomes the first orally administered, breakthrough therapy for both visceral and cutaneous leishmaniasis.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week